Oesophageal Cancer Trial, Recruiting NCT06510543 Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Oesophageal Cancer Trial, Recruiting

NCT06510543
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Be between 18 and 80 years old
  • Be in good enough general health to be reasonably active (confirm with trial site what this means for your situation)
  • Have been identified as being at nutritional risk based on a standard screening tool score (confirm with trial site)
  • Have been diagnosed with malnutrition using a recognised assessment method
  • Have been confirmed by tissue biopsy to have squamous cell cancer of the esophagus (food pipe)
  • Have the cancer located in the chest portion of the esophagus
  • Have a cancer stage that doctors consider suitable for surgery, assessed as stage II to IVA by a specialist team
  • Be planned to receive treatment before surgery, such as chemotherapy, radiotherapy, or immunotherapy (or a combination of these)
  • Be willing to give informed consent and follow the study plan

Who may not be able to join:

  • Those who do not meet the nutritional risk score threshold
  • Those planned to go straight to surgery without any treatment beforehand
  • Those with any health condition that would affect their ability to digest or absorb the study nutritional supplement (ORAL IMPACT®)
  • Those already receiving any other nutritional support during the study period
  • Those unable to eat by mouth or receive nutrition through a feeding tube before surgery
  • Those who have had another cancer in the past 5 years, except certain treated skin cancers or early cervical conditions
  • Those with significantly abnormal liver or kidney function test results (confirm specific values with trial site)
  • Those with uncontrolled diabetes, very high blood sugar, or untreated thyroid problems
  • Those currently taking certain medications including omega-3 fat supplements, glutamine, specific hormones, steroids, or certain biologic medicines (confirm full list with trial site)
  • Those with a known allergy to any ingredient in the study nutritional supplement (ORAL IMPACT®)
  • Women who are pregnant, breastfeeding, or of childbearing age who are not using reliable contraception or have a positive pregnancy test
  • Those unwilling or unable to sign the consent form or follow the study requirements
  • Those considered unsuitable by the study doctors for any other reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Yin Li, M.D., Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phone: +86 13910052790

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Registry
ClinicalTrials.gov
Start date
30 March 2024
Est. completion
30 August 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Rate of postoperative pulmonary complications; Rate of unplanned hospital admissions; Rate of unplanned ICU admission; Overall survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov